Teva CEO Vigodman Steps Down After Poor Outlook for 2017 | Fortune
Teva Prepared to Fight Charges in Generics Probe If Talks Fail - Bloomberg
Teva shares jump in Tel Aviv after report of up to 10,000 job cuts | The Times of Israel
Teva CEO Rejects Netanyahu Plea to Salvage Jerusalem Plant - Bloomberg
Teva Pharma's Short Sellers Double Down as Legal Woes Drag On - Bloomberg
Teva's Adderall Shortage Seen Continuing Into March (TEVA) - Bloomberg
Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
Future Teva CEO Seeks to 'Formulate Clear Strategy' - YouTube
Teva Is Facing Adderall Supply Disruptions as Demand for ADHD Drug Soars - BNN Bloomberg
Israeli pharmaceutical company donating millions of doses of potential coronavirus drug to the U.S.
A bottle of Teva Pharmaceutical Industries Ltd. Clonazepam medication... News Photo - Getty Images
Teva Sees Adderall Supply Delays Continuing for 2-3 Months (1)
Teva flags supply constraints to ADHD drug Adderall as demand rises (NYSE: TEVA) | Seeking Alpha
Teva Shows Progress on Restructuring But Investors Want More - TheStreet
Teva Is 'on the Way' to Leaving Opioid Litigation Behind, CEO Says | Barron's
Teva Is Facing Adderall Supply Disruptions as Demand for ADHD Drug Soars - Bloomberg
Teva looks to sell generics in China through joint venture with Guangzhou Pharma: Bloomberg | Fierce Pharma
Adderall Shortages Spread to 4 Pharmaceutical Companies Including Teva, Novartis - Bloomberg
Teva Pharmaceuticals to pay New York $523 million to settle claims from its role in opioids crisis - ABC News
Teva Pharmaceuticals to Cut 25% of Jobs in Huge Reshaping - The New York Times
Teva Analysts Say Migraine Drug Approval Gives Needed Relief - Bloomberg
Teva Generic Price-Fixing Securities Suit Gets Class Status (1)
Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
